(Q43711828)

26 November 2017

title

Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. (English)

1 reference

26 November 2017

0 references

1 reference

1 reference

chronic heart failure

1 reference

Erdmann E

1

1 reference

26 November 2017

Lechat P

series ordinal

2

1 reference

26 November 2017

Verkenne P

series ordinal

3

1 reference

26 November 2017

Wiemann H

series ordinal

4

1 reference

26 November 2017

publication date

1 August 2001

1 reference

European Journal of Heart Failure

26 November 2017

published in

1 reference

26 November 2017

volume

3

1 reference

26 November 2017

issue

4

1 reference

26 November 2017

page(s)

469-479

1 reference

Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

Rationale for treatment of patients with chronic heart failure with adrenergic blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

Is the prognosis of heart failure improving?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

Has the survival of the heart failure population changed? Lessons from trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

Beta-blockers for congestive heart failure: what is the current consensus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

The treatment and prevention of coronary heart disease in Canada: do older patients receive efficacious therapies? The Clinical Quality Improvement Network (CQIN) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

EDEMA AND DECREASED RENAL BLOOD FLOW IN PATIENTS WITH CHRONIC CONGESTIVE HEART FAILURE: EVIDENCE OF "FORWARD FAILURE" AS THE PRIMARY CAUSE OF EDEMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

Renal function, neurohormonal activation, and survival in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

beta-adrenergic receptor blockade in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

7 January 2021

The effect of digoxin on mortality and morbidity in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

7 January 2021

Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Convert

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

7 January 2021

Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900174-X

7 January 2021

10.1016/S1388-9842(01)00174-X

Identifiers

DOI

1 reference

release_kpsw7teyrzht7owkj4oklrgcve

26 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kpsw7teyrzht7owkj4oklrgcve

24 November 2022

mapped directly with Wikidata item

1 reference